The vaccine landscape: Development, distribution, variants and breakthrough cases, and the road ahead

Explore what’s new

Share this email Share this email on LinkedIn   Share this email on Twitter   Share this email on Facebook   New from McKinsey & Company The vaccine landscape and what’s next The rapid development of COVID-19 vaccines has had a profound effect on the world. As the large scale rollout continues around the world, with 4.32 billion doses administered, new challenges remain around variants including Delta, consumer acceptance and vaccination rates, and global equity. Stay in step with the latest in our special collection on coronavirus vaccines progress, or revisit articles and interactives that look closer at: vaccine distribution across the globe what it will take to end the current pandemic and prevent future ones the future of vaccines and public health systems Read more COVID-19 vaccine distribution Explore the global rollout of COVID-19 vaccinations in comparison to the impact of cases. View the interactive   How might the COVID-19 pandemic end? Experts in healthcare, commerce, security, and more discuss new approaches to address the pandemic when vaccination alone may not be enough and the enduring costs of the crisis continue to rise. Take a holistic approach   Finding solidarity in an effort to vaccinate the world Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance, strengthens ties with partners to help increase global immunity in the context of COVID-19. Address inequities   Africa needs vaccines. What would it take to make them here? For decades, private companies, investors, and public-health leaders have taken a pass on domestic vaccine manufacturing. But a confluence of circumstances may be changing the calculation. Commit to progress   Fast-forward: Will the speed of COVID-19 vaccine development reset industry norms? A review of the funding, operational, technological, and regulatory factors that allowed for fast development of COVID-19 vaccines shows which will remain relevant for future efforts—and which won't. Grasp the dynamics   Not the last pandemic: Investing now to reimagine public-health systems The COVID-19 crisis reminds us how underprepared the world was to detect and respond to emerging infectious diseases. Smart investments of as little as $5 per person per year globally can help ensure far better preparation for future pandemics. 5 shifts   Getting to work: Employers' role in COVID-19 vaccination Employers can consider a set of actions that supports COVID-19-vaccine adoption among employees by building conviction and making vaccination as convenient and "costless" as possible. Gain clarity   When will the COVID-19 pandemic end? This article updates our perspectives on when the coronavirus pandemic will end to reflect the latest information on vaccine rollout, variants of concern, and disease progression. Look ahead   To see more essential reading on topics that matter, visit McKinsey Themes. — Curated by Torea Frey, a managing editor in McKinsey Global Publishing based in Seattle Follow our thinking McKinsey Insights - Get our latest thinking on your iPhone, iPad, or Android Share these insights Did you enjoy this newsletter? Forward it to colleagues and friends so they can subscribe too. Was this issue forwarded to you? Sign up for it and sample our 40+ other free email subscriptions here. This email contains information about McKinsey’s research, insights, services, or events. By opening our emails or clicking on links, you agree to our use of cookies and web tracking technology. For more information on how we use and protect your information, please review our privacy policy. You received this email because you subscribed to our Healthcare Systems & Services alert list. Manage subscriptions | Unsubscribe Copyright © 2021 | McKinsey & Company, 3 World Trade Center, 175 Greenwich Street, New York, NY 10007